TriangleZanubrutinib (NCT06561347)
Zanubrutinib trial for Waldenstrom Macroglobulinemia (NCT06561347). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously untreated Waldenström macroglobulinemia that needs treatment. Any MYD88 or CXCR4 mutation status is allowed.
The idea: daily oral zanubrutinib blocks BTK signaling that supports malignant B cells. Patients also receive intravenous bendamustine and rituximab during the first four cycles; zanubrutinib continues for up to 15 cycles. Those with suspected or symptomatic blood hyperviscosity need plasma exchange first. Researchers assess deep responses and safety.
This phase 2 study plans 65 patients. Andrew Branagan leads at Massachusetts General Hospital in Boston; five US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.